Sign In
Buy AKBA
$0.84
-0.0659 (-7.24%)
At Close: Aug 10, 2026
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:16pm, Tuesday, 03'rd Sep 2024
CAMBRIDGE, Mass. , Sept. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, gra
Here's Why You Should Consider Buying Akebia (AKBA) Stock
11:45am, Monday, 26'th Aug 2024
Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.
Akebia Therapeutics to Present at Upcoming Investor Conferences
08:00am, Monday, 26'th Aug 2024
CAMBRIDGE, Mass. , Aug. 26, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to
5 Small Drug Stocks to Buy as Innovation Reaches Peak
09:20am, Friday, 16'th Aug 2024
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.
Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript
01:00am, Saturday, 10'th Aug 2024
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Investor Relations John Butler - President
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
09:10am, Thursday, 08'th Aug 2024
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.06 per share a year ago.
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
07:00am, Thursday, 08'th Aug 2024
Vafseo ® (vadadustat) Tablets market availability on track for January 2025 TDAPA application submission and WAC pricing announcement for Vafseo complete Second quarter 2024 Auryxia® (ferric citrate
Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights
08:00am, Friday, 02'nd Aug 2024
Akebia to Host Conference Call on August 8, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 01'st Aug 2024
CAMBRIDGE, Mass. , Aug. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, grant
Akebia Therapeutics to Present at Upcoming Investor Conferences
08:00am, Monday, 29'th Jul 2024
CAMBRIDGE, Mass. , July 29, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, t
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets
06:00am, Thursday, 11'th Jul 2024
Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement with CSL Vifor to simplify operational execution and impro
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 01'st Jul 2024
CAMBRIDGE, Mass. , July 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, grant
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
08:18am, Thursday, 27'th Jun 2024
CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
08:58am, Monday, 24'th Jun 2024
CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 03'rd Jun 2024
CAMBRIDGE, Mass. , June 3, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, grante
